Literature DB >> 8394672

Evidence for a role of EGF receptor in the progression of human lung carcinoma.

K Pavelic1, Z Banjac, J Pavelic, S Spaventi.   

Abstract

Sixty-three primary lung carcinomas were examined immunohistochemically for the presence of epidermal growth factor receptors (EGF-R). Of these tumors 35 (55.5%) were positive for EGF-R. A positive correlation between overexpression of EGF-R, on the one hand, and high metastatic rate, poor tumor differentiation and high rate of tumor proliferation, on the other hand, was found. From one tumor with an extremely high amount of EGF-R a primary cell culture was established. The addition of anti-EGF-R serum to this culture decreased cell proliferation. Our results support the evidence for a positive relationship between overexpression of EGF-R and invasiveness, poor differentiation and high growth rate of tumor cells. The blockade of EGF-R with specific antibodies suppressed tumor cell proliferation, suggesting a role of EGF-R in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394672

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  25 in total

Review 1.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.

Authors:  Hang Zhu; Hua Cheng; Yuan Ren; Zhan Guo Liu; Yi Fang Zhang; Bing De Luo
Journal:  Mol Biol Rep       Date:  2011-12-09       Impact factor: 2.316

3.  Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.

Authors:  Enrico Roggero; Giancarla Busi; Busi Giancarla; Antonella Palumbo; Palumbo Antonella; Augusto Pedrazzini; Pedrazzini Augusto
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

Review 4.  Disease proteomics toward bedside reality.

Authors:  Toshihide Nishimura; Atsushi Ogiwara; Kiyonaga Fujii; Takao Kawakami; Takeshi Kawamura; Hisae Anyouji; Harubumi Kato
Journal:  J Gastroenterol       Date:  2005-03       Impact factor: 7.527

5.  ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.

Authors:  Zana K Ahmad; Carrie M Brown; Roberto A Cueva; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-07       Impact factor: 2.311

Review 6.  Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.

Authors:  Eileen Mannion; J J Gilmartin; Paul Donnellan; Maccon Keane; Dympna Waldron
Journal:  Support Care Cancer       Date:  2014-02-22       Impact factor: 3.603

7.  Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.

Authors:  Alicia D Powers; Bi Liu; Andrew G Lee; Sean P Palecek
Journal:  Analyst       Date:  2012-07-20       Impact factor: 4.616

8.  Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.

Authors:  H Swaisland; A Laight; L Stafford; H Jones; C Morris; A Dane; R Yates
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.

Authors:  Edward S Kim; Ann M Mauer; William N William; Hai T Tran; Diane Liu; Jack J Lee; Paul Windt; Waun K Hong; Everett E Vokes; Roy S Herbst
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

10.  EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.

Authors:  Chad A Reade; Apar Kishor Ganti
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.